US 12,083,169 B2
Alkaline phosphatase polypeptides and methods of use thereof
Walter C. Voegtli, Boston, MA (US); Yuhong Wu, Boston, MA (US); Jonathan Monteleone, Boston, MA (US); Tatyana Mezhebovsky, Boston, MA (US); Eric Falcone, Boston, MA (US); and Yang Guo, Boston, MA (US)
Assigned to Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed by Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed on Feb. 10, 2022, as Appl. No. 17/669,275.
Claims priority of provisional application 63/149,090, filed on Feb. 12, 2021.
Prior Publication US 2022/0265784 A1, Aug. 25, 2022
Int. Cl. A61K 38/46 (2006.01); A61K 47/00 (2006.01); A61K 47/02 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61P 19/08 (2006.01); C07K 14/47 (2006.01); C12N 9/16 (2006.01)
CPC A61K 38/465 (2013.01) [A61K 47/02 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61P 19/08 (2018.01); C12N 9/16 (2013.01); C12Y 301/03001 (2013.01); C07K 2319/30 (2013.01)] 29 Claims
 
1. A pharmaceutical composition comprising a dimer comprising a first polypeptide and a second polypeptide, each polypeptide comprising the amino acid sequence of SEQ ID NO: 5, wherein the dimer is linked by a first disulfide bond between C494 of the first polypeptide and C494 of the second polypeptide and a second disulfide bond between C497 of the first polypeptide and C497 of the second polypeptide, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier comprising one or more of phosphate, proline, and sucrose.